Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed as a long-acting analog of native GLP-1, achieved through fatty acid chain modifications that enable albumin binding and extend its plasma half-life. It has been one of the most extensively studied incretin-based compounds in both clinical and preclinical research, with investigations covering type 2 diabetes management, metabolic disease, cardiovascular disease, and non-alcoholic steatohepatitis (NASH).

Research has characterized Semaglutide’s effects on pancreatic beta-cell function, glucagon suppression, gastric emptying delay, and hypothalamic appetite regulation. Cardiovascular outcome trials have established it as a compound of significant interest in cardiovascular risk research in populations with type 2 diabetes and obesity. Preclinical studies have examined its effects on liver lipid accumulation, adipose tissue biology, neuroinflammation, and dopaminergic reward pathways related to food intake behavior.

Semaglutide is one of the most frequently referenced GLP-1 receptor agonists in current metabolic disease research literature. This 10mg research preparation supports extended in vitro studies, receptor pharmacology investigations, and preclinical metabolic research protocols. Researchers examining GLP-1 receptor biology, incretin pharmacology, and metabolic mechanisms commonly reference Semaglutide as a benchmark compound.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.